Gian Manuel Jmz Rdz

👉PCSK9 gene editing: One shot. Lifelong LDL-C lowering? ☝️ A new review explores the promise and challenges of CRISPR-based PCSK9 gene editing. 1️⃣ One-time treatment: A single infusion could provide lifelong reductions in PCSK9 expression and LDL-C. 2️⃣ Early human evidence: VERVE-102 and YOLT-101 have demonstrated substantial LDL-C reductions, reaching approximately 50% at selected doses. 3️⃣ The major advantage: Decades of LDL-C lowering without repeated dosing. A potentially transformative approach to cumulative cholesterol exposure. 4️⃣ Safety considerations: Early clinical results are encouraging. Larger studies and longer follow-up are needed to establish long-term safety and durability. ☝️ The next frontier: Can sustained LDL-C reduction from a single intervention translate into greater lifetime cardiovascular protection? 🔗🔓 doi.org/10.1007/s11883-026-0… @amitvkhera @society_eas